|
|
|
|
|
|
|
|
open access
Discussion
Although
there is evidence for a projected improvement in survival from annual
mammography screening in familial breast cancer (from those largely at
low risk of BRCA1/2) under 50 years of age [17, 18], this is the first time that a prospectively observed reasonably large series of BRCA2
carriers has been shown to have an apparent survival advantage from
annual screening. Recently a Dutch group showed no improvement in
survival, based on only two deaths out of 18 BRCA2 related breast cancers compared to three events in controls [19]. Nonetheless the same group reported that annual mammography screening beyond 60 years of age in BRCA1/2
carriers is associated with a marked improvement in tumour stage at
diagnosis, with 58 % diagnosed at stage two or above with usual
two-yearly screening compared to only 21 % in the annual group [20].
Additionally, the interval cancer rate was doubled by extending
screening to two years. The data from this and the present study concur
with NICE guidelines in England and Wales who recommend annual
mammography for BRCA1/2 carriers until 70 years of age [21]. Although the present study has used a pragmatic comparison group of BRCA2
carriers not undergoing intensive screening a true matched control
series would be impossible as women who knew they were mutation carriers
would be very unlikely to not undergo added surveillance.
The current situation is that no single centre has a series large enough
and well enough constructed and documented to provide a definitive
answer to the question of whether MRI breast screening improves survival
in BRCA2 mutation
carriers. This is why close to all major organisations world-wide
addressing these questions have organised ‘THE BRCA CHALLENGE’ (http://www.humanvariomeproject.org/brca-challenge.html)
which at the 2015 meeting in the UNESCO centre in Paris called for a
broad international collaboration to provide answers to the unanswered
questions. In this context we report our findings and encourage others
to do the same, so as to move our knowledge on effects of interventions
to prevent BRCA2-associated
breast cancer death from assumptions to empirical observed effects of
interventions. Until the time when more definitive answers are available
female BRCA2 carriers will
still require guidance on whether surveillance with MRI and mammography
offers similar improvements in life expectancy than can be gained from
risk reducing surgery [13, 22].
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.